UNITED THERAPEUTICS CORPUTHR
ASignal's systematic analysis rates UTHR as Neutral.
Reflects the latest available analysis · analyzed Sep 5, 2026
The case on UTHR
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong profitability with high gross margin (86.14%) and operating margin (42.23%)
- Exceptional return on equity (19.31%) indicating efficient capital use
- Zero debt and strong cash position ($2.66B) enhancing financial flexibility
- High current ratio (5.73x) and quick ratio (4.89x) signaling robust liquidity
- Free cash flow of $557.14M supports reinvestment and resilience
- Revenue growth declining year-over-year (-1.90%) despite positive earnings growth
- Elevated PEG ratio (2.22x) suggests potential overvaluation relative to growth
- No Reddit mentions, indicating low retail investor interest or visibility
See the full verdict on UTHR
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes UTHR
Most investors never get a second opinion, let alone several. ASignal runs UTHR past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.